TGFB1 and pulmonary fibrosis: The TGF-β1 inhibitor pirfenidone, which is an approved drug for the treatment of idiopathic pulmonary fibrosis, showed anti-fibrotic effects in pre-clinical animal models of fibrosis across organs, namely lung, liver, LV, RV, and kidney (159).